Medozil

Donepezil Hydrochloride, the active ingredient in Medozil, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease in adult patients, helping to improve cognition and function.

GNH USA supplies Medozil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Our distribution network ensures timely delivery and reliable supply chain management.

Donepezil Hydrochloride is an acetylcholinesterase inhibitor used in the management of Alzheimer’s disease.

- Mild Alzheimer’s disease: improves memory and daily functioning. - Moderate Alzheimer’s disease: helps maintain cognition and slows functional decline. - Alzheimer’s disease (overall): provides symptomatic benefit in patients with mild to moderate disease.

Adverse reactions may occur with any medication and should be monitored by the prescribing clinician.

Common Side Effects: - Nausea - Diarrhea - Insomnia - Muscle cramps - Fatigue - Decreased appetite

Serious or Rare Side Effects: - Bradycardia or other cardiac conduction abnormalities - Atrial fibrillation or other arrhythmias - Severe hepatic injury - Seizures - Allergic reactions including rash or angioedema - Hepatic failure

Use of Donepezil requires careful assessment of patient history and comorbid conditions.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic disease: use with caution; assess liver enzymes regularly. - Cardiac conduction disorders: obtain baseline ECG and monitor for bradyarrhythmias. - Seizure history: evaluate risk and observe for seizure activity. - Concurrent cholinergic drugs: assess for additive cholinergic effects. - Store at ambient temperature: keep in original container, protect from moisture and light.

Donepezil may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Anticholinergic agents: reduce Donepezil’s therapeutic effect. - Beta‑blockers: may exacerbate bradycardia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations of Donepezil.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal discomfort. - SSRIs: potential additive nausea. - Diuretics: monitor electrolyte balance and renal function.